Cisen Pharmaceutical Co Ltd Total Assets
Cisen Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Cisen Pharmaceutical Co Ltd (603367) holds total assets worth CN¥7.83 Billion CNY (≈ $1.15 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 603367 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Cisen Pharmaceutical Co Ltd (2011–2025)
Total assets of Cisen Pharmaceutical Co Ltd from 2011 to 2025. This chart illustrates how Cisen Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of Cisen Pharmaceutical Co Ltd for real-time trading data and today's change.
Cisen Pharmaceutical Co Ltd - Asset Composition Analysis
Cisen Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Cisen Pharmaceutical Co Ltd total assets breakdown as of December 2025. Cisen Pharmaceutical Co Ltd's total assets of CN¥7.83 Billion consist of 68.6% current assets and 31.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.0% |
| Accounts Receivable | CN¥542.13 Million | 7.1% |
| Inventory | CN¥623.69 Million | 8.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥196.29 Million | 2.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Cisen Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Cisen Pharmaceutical Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cisen Pharmaceutical Co Ltd's current assets represent 68.6% of total assets in 2025, an increase from 49.4% in 2011.
- Cash Position: Cash and equivalents constituted 16.0% of total assets in 2025, up from 9.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 5.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 8.2% of total assets.
Cisen Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Cisen Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs96.12 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Luoxin Pharmaceuticals Group Stock Co Ltd
SHE:002793
|
China | CN¥3.61 Billion |
Cisen Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.53 | 3.65 | 4.17 |
| Quick Ratio | 4.07 | 3.09 | 3.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.51 Billion | CN¥3.70 Billion | CN¥2.80 Billion |
Cisen Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Cisen Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.99 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 0.6% |
| Total Assets | CN¥7.60 Billion |
| Market Capitalization | $879.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cisen Pharmaceutical Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Cisen Pharmaceutical Co Ltd's assets grew by 0.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cisen Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual total assets of Cisen Pharmaceutical Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.60 Billion ≈ $1.11 Billion |
+0.58% |
| 2024-12-31 | CN¥7.55 Billion ≈ $1.11 Billion |
+2.94% |
| 2023-12-31 | CN¥7.34 Billion ≈ $1.07 Billion |
+7.67% |
| 2022-12-31 | CN¥6.82 Billion ≈ $997.26 Million |
+7.09% |
| 2021-12-31 | CN¥6.36 Billion ≈ $931.21 Million |
+3.21% |
| 2020-12-31 | CN¥6.17 Billion ≈ $902.24 Million |
+11.42% |
| 2019-12-31 | CN¥5.53 Billion ≈ $809.76 Million |
+5.44% |
| 2018-12-31 | CN¥5.25 Billion ≈ $768.00 Million |
+10.68% |
| 2017-12-31 | CN¥4.74 Billion ≈ $693.89 Million |
+44.54% |
| 2016-12-31 | CN¥3.28 Billion ≈ $480.08 Million |
+8.13% |
| 2015-12-31 | CN¥3.03 Billion ≈ $443.97 Million |
+12.64% |
| 2014-12-31 | CN¥2.69 Billion ≈ $394.15 Million |
+13.99% |
| 2013-12-31 | CN¥2.36 Billion ≈ $345.77 Million |
+15.00% |
| 2012-12-31 | CN¥2.05 Billion ≈ $300.67 Million |
+30.50% |
| 2011-12-31 | CN¥1.57 Billion ≈ $230.40 Million |
-- |
About Cisen Pharmaceutical Co Ltd
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and a… Read more